Scholarlink

Background&#xa0; <p>Early detection of metabolic dysfunction-associated steatotic liver disease (MASLD) in newly-diagnosed type 2 Diabetes Mellitus (T2DM), despite offering a therapeutic window, is not extensively studied.&#xa0; </p> Objective <p>The study aimed to define the prevalence and determinants of MASLD in patients with newly diagnosed T2DM.&#xa0; </p> Methods <p>Consecutive patients with newly diagnosed T2DM (≤ 6 months) were enrolled at a tertiary care center and non-invasive hepatic indices were utilized to assess MASLD: hepatic steatosis index (HSI), aspartate aminotransferase to platelet ratio index (APRI), fibrosis 4 index (FIB4), and nonalcoholic fatty liver disease fibrosis score (NFS), along with Fibroscan in a subset of the patients.</p> Results <p>A total of 298 newly diagnosed T2DM patients were included, with a mean age of 51.6 ± 11.5&#xa0;years. Hepatic steatosis was present in 69.7% and fibrosis in 10% of the cohort, with elevated APRI (5.2%) and NFS (13.1%). Hepatic steatosis was strongly correlated with BMI (<i>r</i> = 0.79, <i>p</i> = 0.00). Both FIB4 and APRI showed significant positive correlation with aspartate transaminase and negative correlation with platelets (<i>p</i> &lt; 0.05). High BMI predicted hepatic steatosis (adjusted OR 2.8, 95% CI 1.25 to 6.65, <i>p</i> = 0.012) while AST (adjusted OR 1.1, 95% CI 1.10 to 1.23, <i>p</i> = 0.00) predicted fibrosis.</p> Conclusion <p>There is a significant prevalence of MASLD in newly diagnosed T2DM. Non-invasive tests are valuable, with high sensitivity (steatosis index) and specificity (fibrosis indices).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and determinants of hepatic steatosis and fibrosis due to metabolic dysfunction–associated steatotic liver disease (MASLD) in newly diagnosed type 2 diabetes mellitus

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Liza Das,
  • Biona Devi Konsam,
  • Tushar Bhadada,
  • Ashish Kumar Bhagat,
  • Jasbir Singh,
  • Rimesh Pal,
  • Shruti Sharma,
  • Pinaki Dutta,
  • Ajay Duseja,
  • Sanjay Kumar Bhadada

摘要

Background 

Early detection of metabolic dysfunction-associated steatotic liver disease (MASLD) in newly-diagnosed type 2 Diabetes Mellitus (T2DM), despite offering a therapeutic window, is not extensively studied. 

Objective

The study aimed to define the prevalence and determinants of MASLD in patients with newly diagnosed T2DM. 

Methods

Consecutive patients with newly diagnosed T2DM (≤ 6 months) were enrolled at a tertiary care center and non-invasive hepatic indices were utilized to assess MASLD: hepatic steatosis index (HSI), aspartate aminotransferase to platelet ratio index (APRI), fibrosis 4 index (FIB4), and nonalcoholic fatty liver disease fibrosis score (NFS), along with Fibroscan in a subset of the patients.

Results

A total of 298 newly diagnosed T2DM patients were included, with a mean age of 51.6 ± 11.5 years. Hepatic steatosis was present in 69.7% and fibrosis in 10% of the cohort, with elevated APRI (5.2%) and NFS (13.1%). Hepatic steatosis was strongly correlated with BMI (r = 0.79, p = 0.00). Both FIB4 and APRI showed significant positive correlation with aspartate transaminase and negative correlation with platelets (p < 0.05). High BMI predicted hepatic steatosis (adjusted OR 2.8, 95% CI 1.25 to 6.65, p = 0.012) while AST (adjusted OR 1.1, 95% CI 1.10 to 1.23, p = 0.00) predicted fibrosis.

Conclusion

There is a significant prevalence of MASLD in newly diagnosed T2DM. Non-invasive tests are valuable, with high sensitivity (steatosis index) and specificity (fibrosis indices).